For more than two decades, millions of women have been told that hormone replacement therapy (HRT) after menopause is dangerous.

The turning point was the Women’s Health Initiative (WHI) study published in 2002. Media headlines around the world warned that estrogen therapy caused cancer and should be avoided.

The result was immediate and dramatic. Prescriptions for HRT collapsed almost overnight.

But according to physicians and researchers like Avrum Bluming, author of Estrogen Matters, much of the public narrative surrounding the WHI was deeply misleading. In fact, Bluming and other researchers argue that misinterpretation of the data deprived millions of women of therapies that could protect their health and quality of life.

The story of the WHI illustrates a broader problem: the politicization of women’s health.

What the Women’s Health Initiative Actually Found

The WHI was designed to evaluate the effects of hormone therapy on post-menopausal women. Early reports focused heavily on a small increase in breast cancer risk in a subgroup of women taking combined estrogen-progestin therapy.

But several critical details were lost in the media coverage:

Many participants were well past menopause, often in their 60s and 70s, when hormone therapy was first introduced.

Many participants were well past menopause, often in their 60s and 70s, when hormone therapy was first introduced.

Later analysis found no increased breast cancer risk in women taking estrogen alone.

Later analysis found no increased breast cancer risk in women taking estrogen alone.

Follow-up research showed that timing matters: starting HRT closer to menopause may carry significant benefits.

Follow-up research showed that timing matters: starting HRT closer to menopause may carry significant benefits.

According to Bluming and colleagues, the broader evidence suggests that properly

prescribed estrogen therapy may:

Reduce risk of cardiovascular disease

Reduce risk of cardiovascular disease

Help protect against Alzheimer’s disease

Help protect against Alzheimer’s disease

Prevent osteoporosis and osteopenia

Prevent osteoporosis and osteopenia

Improve urogenital health and prevent painful vaginal atrophy

Improve urogenital health and prevent painful vaginal atrophy

Reduce recurrent urinary tract infections

Reduce recurrent urinary tract infections

These are not trivial issues. After menopause, declining estrogen can cause vaginal tissue thinning and dryness that can lead to chronic pain, sexual dysfunction, and repeated infections. HRT can alleviate these problems for many women.

Yet the public narrative remained simple: estrogen causes cancer.

The fear generated by the WHI had measurable consequences.

HRT use dropped dramatically worldwide. Many physicians became reluctant to prescribe it even when medically appropriate. Millions of women endured untreated symptoms that significantly affected their health and quality of life.

The irony is that the backlash often emerged from political activism that framed hormone therapy as something imposed by male doctors in a patriarchal medical system.

But the reality of medical history is more complicated.

Many of the medical innovations that protect women’s reproductive health—including hormonal birth control—were developed by male physicians and scientists. Scientific progress has never been a simple gender battle.

When medicine becomes filtered through ideological narratives, nuance is lost.

A History of Politicizing Women’s Medicine

The WHI controversy is not the first time activism has influenced women’s health policy in ways that produced unintended consequences.

The Birth Control Approval Controversy

In the early years of hormonal birth control, activists argued that regulatory processes delaying approval were discriminatory toward women. Political pressure mounted on regulators in both the United States and the United Kingdom.

Governments eventually accelerated approval.

However, early formulations of synthetic estrogen had not been studied as extensively as modern standards would require. Some women who used these early compounds later developed serious health complications, including reproductive cancers. Synthetic estrogen compounds used in early contraceptives were also prescribed for menopausal symptoms.

The episode illustrates a recurring tension: when political urgency overrides careful medical evaluation, women may bear the risks.

The “Female Viagra” Campaign

A more recent example involved Flibanserin, marketed under the brand name Addyi.

The drug was promoted as “female Viagra,” though the comparison was misleading. Viagra treats erectile dysfunction, while flibanserin was designed to treat low sexual desire.

Clinical trials showed that the drug produced only modest benefits—on average about 1.5 additional satisfying sexual encounters per month—while producing significant side effects such as dizziness, fainting, fatigue, insomnia, and nausea.

The pharmaceutical company that originally developed the drug concluded the risks outweighed the benefits and abandoned development.

Activist campaigns soon followed, arguing that regulators were biased against treatments for women’s sexuality. Under intense political pressure, the U.S. Food and Drug Administration eventually approved the drug.

Again, the pattern appeared: activism pushing regulatory bodies toward decisions that many medical experts believed were premature.

When Ideology Overrides Evidence

The debate over hormone therapy reflects another form of politicization.

Some activists framed menopause treatment as an attempt by a patriarchal medical system to keep women sexually attractive to men. In this framing, rejecting hormone therapy became a form of resistance.

But women’s health should not be sacrificed to ideological symbolism.

Post-menopausal estrogen therapy is not about pleasing men. It is about managing legitimate medical conditions affecting bones, cardiovascular health, cognition, and urogenital tissue.

The scientific reality is nuanced.

HRT is not appropriate for every woman. Certain conditions—such as specific cancer histories or clotting disorders—may make hormone therapy unsafe. Decisions should always be made between patients and qualified physicians.

But rejecting HRT outright because of politicized narratives is just as harmful as prescribing it indiscriminately.

Science Should Lead Women’s Health

The history of women’s medicine contains an uncomfortable lesson: when ideological movements—whether pharmaceutical, political, or activist—override scientific evidence, women can pay the price.

The backlash against HRT following the Women’s Health Initiative shows how quickly complex research can be simplified into a frightening narrative.

Books like Estrogen Matters remind us that science evolves. Evidence accumulates. Early conclusions are revised.

Women deserve accurate information about the risks and benefits of hormone therapy, not narratives driven by political agendas or cultural battles about patriarchy.

Healthcare should never become collateral damage in ideological wars.

Women deserve better than that.

© The Times of Israel (Blogs)